Education
About Us
Working with TipRanks
Follow Us
Xintela AB (SE:XINT)
:XINT
XINT Stock Chart & Stats
kr0.25
-kr0.02(-4.02%)
At close: 4:00 PM EST
kr0.25
-kr0.02(-4.02%)
Day’s Range― - ―
52-Week Rangekr0.24 - kr0.70
Previous CloseN/A
Volume22.80K
Average Volume (3M)554.92K
Market Cap
kr248.77M
Enterprise Valuekr279.09M
Total Cash (Recent Filing)kr3.38M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Feb 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding979,390,560
10 Day Avg. Volume503,836
30 Day Avg. Volume554,918
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-31.80
Price to Sales (P/S)44.88
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Xintela AB News
XINT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was kr0.24 and its highest was kr0.70 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is kr248.77M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is Feb 27, 2026 which is in 74 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on Nov 04, 2025. The company reported -kr0.01 earnings per share for the quarter, beating the consensus estimate of -kr0.02 by kr0.01.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is -0.01.
How many shares outstanding does Xintela AB have?
Xintela AB has 979,390,560 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of -kr0.01 in its last earnings report, beating expectations of -kr0.02. Following the earnings report the stock price went down -6.236%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in SE:XINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (XINT) is a biotechnology company based in Sweden that focuses on the development and commercialization of cell therapy products and targeted cancer treatments. The company leverages its proprietary marker technology, XINMARK, to identify and select specific cell types for therapeutic use, primarily in the fields of regenerative medicine and oncology. Xintela's core products and services revolve around stem cell-based therapies for osteoarthritis and other musculoskeletal disorders, as well as targeted antibodies for the treatment of aggressive cancers.
Technical Analysis
Isofol Medical AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―